Accell Clinical Research Expands the Use of the CTMS Platform by Flex Databases
Flex Databases, a company specialising in Professional Services Automation (PSA) for pharmaceutical industry, announced today that Accell Clinical Research are expanding the use of the Flex CTMS platform to include its innovative Project Management module.
Accell is a CRO headquartered in St. Petersburg, Russia and active in Russia, Ukraine and Baltic States.
"We have been working with Flex since July 2012," said Natalia Nayanova, Director of Clinical Operations and General Manager of Accell Clinical Research. "We are going through an active growth phase, and last year we decided that it was time to acquire a platform allowing us to standardise both our internal and external processes. We looked at the market and Flex Databases were the best available choice for us. Although many factors contributed to our decision (clinical trial experience of the Flex team, their knowledge of the CRO business, flexibility of their platform), we felt that the biggest advantage they brought was the Professional Services Automation functionality — the ability to manage all the aspects of running a service organisation together with the clinical trial process. We are extending the use of the Flex platform by licensing their Project Management module - this will allow us to have full visibility of our projects and have all the relevant information centrally available, in an environment configured for our needs."
"We are thrilled to be expanding our relationship with Accell," said Timur Galimov, Technical Director of Flex Databases. "It has been a pleasure to work with Accell who are a dynamic company open to innovation. We are glad to see them leverage the full potential of our platform by adding Project Management, gaining access to features such as bid grid tool, resource planning, dynamic Gantt tables and automated budget updates. Accell took an active role in the relationship, feeding back ideas to us and sharing our enthusiasm for cutting edge technology, and we are pleased to be a part of their success."
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance